Skip to content

Glucose Control in Severely Burned Patients

Glucose Control in Severely Burned Patients: Mechanisms and Therapeutic Potential

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01307306
Enrollment
45
Registered
2011-03-02
Start date
2011-03-31
Completion date
2018-03-31
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Keywords

Thermal injury, Chemical Burn, Flame Burn

Brief summary

The central aim of this application is to determine whether improved outcomes with tight euglycemic control are due to insulin-specific responses. The investigators hypothesize that improving insulin resistance will lead to decreased inflammatory and hypermetabolic responses, as well as restored glucose metabolism, and so result in improved clinical outcome of severely burned patients.

Interventions

Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.

DRUGMetformin

Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.

Sponsors

Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* between 18 and 90 years of age * \>20% TBSA * Admitted to the burn unit within 120 hours following burn * At least 1 surgical intervention necessary

Exclusion criteria

* death upon admission * decision not to treat due to burn injury severity * presence of anoxic brain injury that is not expected to result in complete recovery * known history of AIDS, ARC, HIV, Hepatitis B-E * history of cancer within 5 years of malignancy currently under treatment * inability to obtain informed consent * previous or existing renal dysfunction, liver disease, or hepatic dysfunction * pre-existing type I diabetes mellitus * pregnancy * allergy to metformin

Design outcomes

Primary

MeasureTime frameDescription
Perform oral glucose tolerance testat 1-2 months post-admission, up to 6 monthsStandard fasting oral glucose tolerance test with an intake of 75 g of glucose. Subsequent measurements (in mg/dl) of glucose in blood, insulin and c-peptide will be conducted over 2 hours.

Secondary

MeasureTime frameDescription
Measure concentrations of serum cytokinesweekly until discharge (1-4 months post admission depending on severity of injury)Inflammatory response will be assessed by measuring the concentrations (in pg/ml)of a panel of serum cytokines (IL-1, IFN, TNF etc.) using the Bio-Plex 17-Plex Suspension assay.
Record the episodes of sepsisdaily until discharge (1-4 months post admission depending on severity of injury)Patients will be assessed daily for episodes of sepsis. The total number of episodes over the course of hospital stay will be recorded.
Record the episodes of Pneumoniadaily until discharge (1-4 months post admission depending on severity of injury)Pneumonia is defined by new progressive and persistent infiltrate, consolidation or cavitations, inhalation injury based on chest X-ray. We will also follow the guidelines provided by the American Burn Association on the definition of Pneumonia in burn patients. Change in sputum (purulent or increased) will also be recorded.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026